User:Mr. Ibrahem/Oliceridine

Mr. Ibrahem/Oliceridine
Clinical data
Pronunciation	OH li SER i deen
Trade names	Olinvyk
Other names	Oliceridine fumarate, TRV-130, TRV130
AHFS/Drugs.com	Monograph
License data	US DailyMed: Oliceridine;
Addiction; liability	High
Routes of; administration	Intravenous
Drug class	Opioid agonist
Legal status
Legal status	US: Schedule II;
Pharmacokinetic data
Onset of action	2 to 5 min
Duration of action	1 to 3 hrs
Identifiers
	IUPAC name N-[(3-Methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine;
Chemical and physical data
Formula	C22H30N2O2S
Molar mass	386.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1ccsc1CNCC[C@]2(CCOC3(CCCC3)C2)c4ccccn4;
	InChI InChI=1S/C22H30N2O2S/c1-25-18-7-15-27-19(18)16-23-13-10-21(20-6-2-5-12-24-20)11-14-26-22(17-21)8-3-4-9-22/h2,5-7,12,15,23H,3-4,8-11,13-14,16-17H2,1H3/t21-/m1/s1; Key:DMNOVGJWPASQDL-OAQYLSRUSA-N;

Oliceridine, sold under the brand name Olinvyk, is an opioid medication used to treat moderate to severe acute pain.^[1] Due to the risk of side effects, it should only be used when other options are not possible.^[1] It is given by injection into a vein.^[1]

Common side effects include nausea, dizziness, headache, constipation, itchiness, and low oxygen.^[1] Other side effects may include abuse, QT prolongation, respiratory depression, low blood pressure, serotonin syndrome, and sedation.^[1] It interacts with benzodiazepines and alcohol.^[1] Use during pregnancy may result in neonatal opioid withdrawal syndrome.^[1]

Oliceridine was approved for medical use in the United States in 2020.^[1] In the United States it costs about 28 USD for 2 mg as of 2022.^[3] In the United States it is a Schedule II controlled substance.^[1]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p "Olinvyk- oliceridine injection, solution". DailyMed. 18 August 2020. Archived from the original on 22 January 2022. Retrieved 16 September 2020.
^ Tan, HS; Habib, AS (2021). "Oliceridine: A Novel Drug for the Management of Moderate to Severe Acute Pain - A Review of Current Evidence". Journal of pain research. 14: 969–979. doi:10.2147/JPR.S278279. PMID 33889018.{{cite journal}}: CS1 maint: unflagged free DOI (link)
^ "Olinvyk Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 24 January 2022. Retrieved 3 November 2022.

[PI2022-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l ^m ⁿ ^o ^p "Olinvyk- oliceridine injection, solution". DailyMed. 18 August 2020. Archived from the original on 22 January 2022. Retrieved 16 September 2020.

[Tan2019-2] Tan, HS; Habib, AS (2021). "Oliceridine: A Novel Drug for the Management of Moderate to Severe Acute Pain - A Review of Current Evidence". Journal of pain research. 14: 969–979. doi:10.2147/JPR.S278279. PMID 33889018.{{cite journal}}: CS1 maint: unflagged free DOI (link)

[3] "Olinvyk Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 24 January 2022. Retrieved 3 November 2022.

[1]

[2]

[3]